Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR etc. |
| Sample | lung adenocarcinoma tissues, cell lines (H1299, H1975, A549 and H1650) |
| Expression Pattern | up-regulated |
| Function Description | Linc00152 was upregulated in lung adenocarcinoma. Linc00152 independently predicts poor prognosis and promotes tumor progression in lung adenocarcinoma. Linc00152 needs to be considered as a potential molecular target in future cancer pharmacology. Overexpression of Linc00152 in lung cancer cells stimulated proliferation, tumor cell invasion and migration. Knockdown of Linc00152 inhibited cell growth and cell invasion and migration.Kaplan-Meier and Cox proportional hazards analyses were used to analyze the overall survival (OS) and disease-free survival (DFS) rates. |
| Pubmed ID | 28819405 |
| Year | 2017 |
| Title | Linc00152 promotes Cancer Cell Proliferation and Invasion and Predicts Poor Prognosis in Lung adenocarcinoma. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |